Holen Sie sich die Stockscreener-App
36.94
16.78%
-7.45
Handel nachbörslich:
37.10
0.16
+0.43%
Exelixis Inc Aktie (EXEL) Neueste Nachrichten
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT - MSN
U.S. Indexes Decreased Tuesday; Exelixis Posted Biggest Loss - Barron's
Exelixis outlines continued cabozantinib growth and zanzalintinib pipeline acceleration as new launches drive 19% revenue increase - MSN
Exelixis stock price target lowered to $45 at RBC on lifecycle cuts - Investing.com Canada
Truist Securities lowers Exelixis stock price target to $49 on mixed results - Investing.com Canada
Exelixis stock price target raised to $41 from $38 at Stifel on NET launch - Investing.com Canada
Exelixis Stuns Analyst With Q2 Miss, Trial Delays, Phase 3 HaltExelixis (NASDAQ:EXEL) - Benzinga
All You Need to Know About Exelixis (EXEL) Rating Upgrade to Strong Buy - Yahoo Finance
EXEL Q2 Earnings Top, Sales Miss on Lower Collaboration Revenues - The Globe and Mail
Is Exelixis Inc. Forming a Consolidation BaseTop Performing Stock Insights Released Daily - metal.it
Exelixis leans on zanzalintinib as cabozantinib nears patent expiry - S&P Global
Exelixis shares tumble over 12% after revenue miss and zanzalintinib trial halt - MSN
Whirlpool Posts Downbeat Earnings, Joins Harmonic, Stanley Black & Decker And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
S&P 500 Futures Climb in Premarket Trading; Whirlpool, Exelixis Lag - Barron's
Exelixis fall over 12% after revenue miss, halts zanzalintinib trial By Investing.com - Investing.com India
UnitedHealth, Sarepta, UPS, Whirlpool, VeriSign, Cadence Design, Exelixis, and More Market Movers - Barron's
Exelixis stock rating reiterated by JMP analyst despite sales miss - Investing.com Nigeria
Exelixis Shares Plunge 12.14% on Revenue Miss - AInvest
Exelixis 2025 Q2 Earnings Mixed Performance as Net Income Declines 18% - AInvest
Exelixis Q2 Revenue Falls 11 Percent - AOL.com
Exelixis Inc (EXEL) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Challenges - Yahoo Finance
Exelixis’s SWOT analysis: cabo success, zanza potential drive stock outlook - Investing.com
Exelixis Reports Q2 2025 Financial Results and Updates - TipRanks
Exelixis: Q2 Earnings Snapshot - The Washington Post
Exelixis Beats On Earnings As Cancer Drugs Drive Growth - Finimize
Earnings call transcript: Exelixis beats EPS forecasts in Q2 2025 - Investing.com
Exelixis slides 12% on Q2 miss, pipeline update (EXEL:NASDAQ) - Seeking Alpha
Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - BioSpace
After-hours movers: Western Union, Whirlpool, Exelixis, and more By Investing.com - Investing.com Canada
Exelixis (EXEL) Beats Q2 Earnings Estimates - Yahoo Finance
Exelixis Q2 Earnings: Surpassing Expectations Amid Revenue ChallengesNews and Statistics - IndexBox
How strong is Exelixis Inc. company’s balance sheetRetirement Planning Insights For 2025 - jammulinksnews.com
EXELIXIS, INC. SEC 10-Q Report - TradingView
Exelixis shares tumble as revenue miss and weak guidance disappoint - Investing.com Australia
Exelixis shares tumble as revenue miss and weak guidance disappoint By Investing.com - Investing.com India
Exelixis earnings beat by $0.11, revenue fell short of estimates - Investing.com Canada
Exelixis Q2 2025 Financial Results and Corporate Update - TradingView
Exelixis Q2 adjusted EPS beats expectations - MarketScreener
Should I hold or sell Exelixis Inc. stock in 2025Top Growth Entry Points For Every Investor - jammulinksnews.com
Here's Why Exelixis (EXEL) is a Strong Momentum Stock - sharewise.com
Published on: 2025-07-28 16:17:28 - metal.it
Is it the right time to buy Exelixis Inc. stockSuperior returns - jammulinksnews.com
Why is Exelixis Inc. stock attracting strong analyst attentionSwing Trade Opportunities From AI Tools - jammulinksnews.com
Exelixis, Inc. (EXEL) Stock Analysis: A Biotech Powerhouse with a 30% Revenue Growth Surge - DirectorsTalk Interviews
Cushing Syndrome Market Trends is Electrifying Growth Cycle: Bristol Myers Squibb, Exelixis, Diurnal Group - openPR.com
How does Exelixis Inc. compare to its industry peersRapid growth opportunities - jammulinksnews.com
What is Exelixis Inc. company’s growth strategyMaximize gains with data-driven stock picks - jammulinksnews.com
Published on: 2025-07-28 02:15:22 - jammulinksnews.com
What markets is SMFG expanding into Is Exelixis Inc. stock a good long term investment optionGet daily expert analysis for smarter investing - jammulinksnews.com
What makes Exelixis Inc. stock price move sharplyMaximize gains with expert analysis - jammulinksnews.com
Exelixis Q2 2025 Earnings Preview: Revenue Down 9.2% YoY, EPS Down 23.8% YoY - AInvest
Exelixis Inc. Stock Analysis and ForecastBreakthrough capital growth - PrintWeekIndia
10.28%
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):